Evaluation of the Sensitivity to Different Chemotherapy Regimens in Platinum-Partial Sensitive Recurrent Ovarian Cancer

• Status: Recruiting
• Trial end date: 2021-06-01
• Target enrollment: 0
• Participant gender: All

Summary

Multicenter, prospective, randomized studies.Evaluation of the sensitivity to different chemotherapy regimens in platinum-partial sensitive recurrent ovarian cancer based on 11 gene tests of homologous recombination pathway.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hunan Cancer Hospital
• Treatments: Albumin-Bound Paclitaxel; Carboplatin; Doxorubicin; Liposomal doxorubicin; Paclitaxel

Criteria

Inclusion Criteria:

1. age: 18-75 years old

2. PS score: ECOG 0 ~ 2

3. histopathologically confirmed primary high-grade serous adenocarcinoma or high-grade endometrioid adenocarcinoma of the ovary, fallopian tube or peritoneum;

4. the time interval between this recurrence and the last chemotherapy was 6-12 months;

5. evaluate the ability of bone marrow, liver, kidney, heart and other important organ functions to withstand chemotherapy;

6. expected survival over 3 months;

7. sign the informed consent.

Exclusion Criteria:

1. brain metastasis or the presence of symptoms caused by brain metastasis;

2. serious complications;

3. acute inflammatory reaction;

4. other tumors;

5. a history of allergy to paclitaxel or polyropyridone liposomes;